Lisata Therapeutics Sets 1-for-15 Reverse Stock Split, Effective Nov. 23

Split-adjusted trading begins Nov. 23 under the existing LSTA ticker, with a new CUSIP of 128058 401.

Interior of modern research laboratory. People at work in the scientific laboratory
Photo: Pedal to the Stock/Shutterstock.com

Key terms

  • Ratio: one-for-fifteen, effective 12:01 a.m. ET, Nov. 23
  • Split-adjusted trading begins Nov. 23 under LSTA
  • New CUSIP 128058 401; fractions paid in cash
  • Shares outstanding: about 10.8 million to about 0.7 million

Lisata Therapeutics (Nasdaq: LSTA) will carry out a one-for-fifteen reverse stock split effective Nov. 23, the company said in an 8-K filed Thursday.

The company filed a certificate of amendment with the Delaware Secretary of State on Nov. 19. The split takes effect at 12:01 a.m. Eastern Time on Nov. 23. Common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market at market open that day, under the existing ticker LSTA.

Stockholders approved the split at the company's 2026 annual meeting on Nov. 9. They authorized a ratio between one-for-five and one-for-fifteen, and the board set the ratio at one-for-fifteen.

What changes for holders

Every fifteen shares outstanding will be combined into one share. The company said shares outstanding will fall from about 10.8 million to about 0.7 million. Par value and the total number of authorized shares will not change. The filing says the split will not affect any holder's percentage ownership, except for minor changes from fractional shares.

No fractional shares will be issued. Holders who would otherwise receive one will get a cash payment equal to the fractional interest multiplied by the closing price on Nasdaq Capital Market on Nov. 19.

Before the filing, the company's market value was about $10.6 million, based on the $0.98 close on Nov. 18 and about 10.8 million shares.

Ticker, CUSIP and rights

The ticker stays LSTA. The new CUSIP number is 128058 401. Securities convertible into or exercisable for common stock will be adjusted under their terms.

Sources

Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.

LSTA page →

Filings, figures and price history are on the Lisata Therapeutics page.